Protara Therapeutics, Inc. — Investor Relations & Filings

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing transformative therapies for cancer and rare diseases. The company's lead candidate is TARA-002, an investigational cell therapy based on the immunopotentiator OK-432. TARA-002 is being evaluated for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), for which it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Protara's pipeline also includes IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients on parenteral support who are choline deficient, with the potential to become the first FDA-approved intravenous choline formulation for this patient group.